The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Lack of Treatment Persistence and Treatment Nonadherence as Barriers to Glycaemic Control in Patients with Type 2 Diabetes
Open accessAbstract
Treatment persistence (continuing to take medication for the prescribed period) and treatment adherence (complying with the prescription in terms of drug schedules and dosage) are both important when treating chronic diseases such as type 2 diabetes (T2D). They can be indicators of patient satisfaction with treatment. In T2D, the achievement of optimal outcomes requires both persistence with and adherence to prescribed therapy. Poor persistence with and adherence to T2D medication can have profound consequences for the patient, including non-achievement of glycaemic goals and an increased risk of long-term complications and mortality. Therefore, poor treatment persistence and adherence may also have economic consequences, including increased healthcare resource utilization and healthcare costs. Treatment persistence and adherence are affected by several factors, including the mode of administration, administration frequency/regimen complexity, and patient expectations. The aims of this review are as follows: to provide an overview of persistence with and adherence to different antidiabetes therapies for patients with T2D in the real-world setting; examine factors contributing to poor treatment persistence and adherence; and assess available data on the impact of poor treatment persistence and/or adherence on clinical and economic outcomes. Numerous potential targets for improving treatment persistence and/or adherence are identified, including developing less complex treatment regimens with lower pill burdens or less frequent injections, improving the convenience of drug-delivery systems, such as the use of insulin pen devices rather than the conventional vial and syringe, and developing therapies with an improved safety profile to alleviate patient fears of adverse effects, such as weight gain and risk of hypoglycaemia.Funding: Sanofi.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lack of adherence and persistence with treatment in T2DM acts as a barrier to achieving glycaemic control [6], increases the risk of microvascular and macrovascular complications [7], and increases healthcare costs [5, 8].”
In the citing paper
“In people with T2DM who discontinue or do not properly adhere to their therapy, there is an increased risk of microvascular and macrovascular complications [7], which can in turn increase healthcare costs further [5, 6].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Medication compliance and persistence: terminology and definitions
Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00213.x · Cited by 2,220
Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost
Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005) · Medical Care · doi:10.1097/01.mlr.0000163641.86870.af · Cited by 1,729
Adherence to Therapies in Patients with Type 2 Diabetes
García‐Pérez, L., Álvarez, M., Dilla, T., Gil-Guillén, V. F., & Orozco‐Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 783
Nicolucci, A., Kovacs Burns, K., Holt, R. I. G., Comaschi, M., Hermanns, N., Ishii, H., Kokoszka, A., Pouwer, F., Skovlund, S. E., Stuckey, H., et al. (2013) · Diabetic Medicine · doi:10.1111/dme.12245 · Cited by 739
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M. A., Peters, A. L., Τσάπας, Α., Wender, R. C., & Matthews, D. R. (2015) · Diabetologia · doi:10.1007/s00125-014-3460-0 · Cited by 701
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655
Davies, M. J., Gagliardino, J. J., Gray, L. J., Khunti, K., Mohan, V., & Hughes, R. (2013) · Diabetic Medicine · doi:10.1111/dme.12128 · Cited by 302
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc17-s009 · Cited by 279
Lee, W. C., Balu, S., Cobden, D., Joshi, A. V., & Pashos, C. L. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.10.004 · Cited by 262
Research works printed but not linked: 1
- Reynolds SL, Zhou S, Uribe C, Li Y. Impact of insulin delivery systems in elderly patients with type 2 diabetes. Am J Pharm Benefits. 2015;7:222–31.
Cited by
Sorted by citations
Items 101–106 of 106
Use of technology and AI tools in type 2 diabetes
Kesavadev, J., Mohamed Abdul Khader, M., & Basanth, A. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102130
Mauricio, D., Pascual, V., Soler, M., & Pérez‐Sádaba, F. J. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01892-2
Shanmugam, P., Adams, R. N., Athinarayanan, S. J., Wolfberg, A., & Ballreich, J. M. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01909-w
Insulin pens and the digital ecosystem
JENDLE, J. H., Adolfsson, P., Cardona‐Hernandez, R., Crenier, L., Molfetta, S. D., Ehrmann, D., Giorgino, F., Haluzı́k, M., Hirsch, I. B., Irace, C., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06858-4
Lee, J., Ashraf, S., Kim, E., Lee, H. J., Park, J., Jeon, H. J., Suh, S., & Park, S. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103710
Himali, N. A., Al-Habsi, H., Mushrafi, A. A., Shidi, A. A., Abbas, A., Kindi, A. A., Sayid, H., Mohammadi, I., Subhi, A. A., & Kiyumi, M. H. A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15207797
Metadata
- Authors
- Guerci, B., Chanan, N., Kaur, S., Jasso-Mosqueda, J. G., & Lew, E.
- Affiliations
- Inserm (FR)
- Sanofi (France) (FR)
- Corresponding author
- Guerci, Bruno
- Venue
- Diabetes Therapy
- Published
- 2019-03-08
- Volume
- 10
- Issue
- 2
- Pages
- 437-449
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC6437240
- OpenAlex
- W2922388296
- Cited by
- 106
- References
- 65
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 11 · 2023: 12 · 2022: 16 · 2021: 23 · 2020: 14 · 2019: 3
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 2 diabetes, treatment persistence, medication adherence, glycemic control, medication burden, insulin pen devices, drug delivery systems, patient expectations, adverse drug reactions, hypoglycemia, health care costs, real-world evidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
